中国医学科学院学报2013，Vol.35Issue(2)：229-233,5.DOI:10.3881/j.issn.1000-503X.2013.02.019
二肽基肽酶-Ⅳ抑制剂的降糖机制研究进展
Research Progress of Mechanisms through which Dipeptidyl Peptidase-Ⅳ Inhibitors Regulate Glycemia
王结胜1
作者信息
- 1. 浙江省立同德医院干部保健科,杭州,310012
- 折叠
摘要
Abstract
Corresponding author; WANG Jie-sheng Tel: 0571-89972437, E-mail: wwjjss2000@163. com
Dipeptidyl peptidase-Ⅳ (DPP-Ⅳ) inhibitors are promising new antidiabetic drugs. It had been proposed that DPP-Ⅳ inhibitors exert their antidiabetic effect by inhibiting the degradation of glucagon-like peptide 1 (GLP-1) . However, new evidence has shown that the increase of GLP-1 is not notable after the use of these drugs in patients with type 2 diabetes. Therefore, the specific mechanisms via which DPP-Ⅳ inhibitors in controlling blood glucose has became questionable. In recent years, studies have revealed many possible mechanisms through which DPP-Ⅳ inhibitors regulate glycemia: DPP-Ⅳ inhibitors may selectively reduce DPP-Ⅳ activity in the intestine, causing the increase of portal plasma GLP-1 level and thus promoting the release of insulin via nerve reflex; also, they may decrease the cleavage product of GLP-1 and reduce the degradation of other bioactive peptides.关键词
胰高血糖素样肽-1/二肽基肽酶-Ⅳ/血糖调节Key words
glucagon-like peptide 1/ dipeptidyl peptidase-IV/ regulate glycemia分类
医药卫生引用本文复制引用
王结胜..二肽基肽酶-Ⅳ抑制剂的降糖机制研究进展[J].中国医学科学院学报,2013,35(2):229-233,5.
